tiprankstipranks
Trending News
More News >

Solvonis Launches AI-Driven CNS Drug Discovery Initiative

Story Highlights
  • Solvonis Therapeutics initiates AI-supported drug discovery using its CNS compound library.
  • The program aims to identify high-value candidates for neuropsychiatric conditions like depression.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Solvonis Launches AI-Driven CNS Drug Discovery Initiative

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Graft Polymer (UK) PLC ( (GB:SVNS) ).

Solvonis Therapeutics plc has initiated an AI-supported drug discovery program centered on its proprietary CNS compound library, acquired from Awakn Life Sciences Corp. This program aims to accelerate the identification and optimization of high-value development candidates for neuropsychiatric conditions such as depression and stimulant use disorders. The initiative, led by Professor David Nutt, enhances Solvonis’ R&D pipeline, complementing existing programs and reflecting the company’s strategy to combine innovation with rigorous science to address significant mental health challenges.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet need, including Alcohol Use Disorder and Post-Traumatic Stress Disorder.

Average Trading Volume: 22,961,744

Technical Sentiment Signal: Sell

Current Market Cap: £8.42M

Find detailed analytics on SVNS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1